On March 27, 2025, Dermata Therapeutics announced positive topline results from its Phase 3 trial of XYNGARI for treating moderate-to-severe acne, showing significant improvements over placebo. The trial involved 520 patients and met all primary endpoints, with plans for a second trial in late 2025.